Cargando…

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans

Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, there remains a need for more prevention and treatment options for individuals remaining at risk of coronavirus disease 2019 (COVID-19). Monoclonal antibodies (mAbs) against the viral spike protein have pot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loo, Yueh-Ming, McTamney, Patrick M., Arends, Rosalinda H., Abram, Michael E., Aksyuk, Anastasia A., Diallo, Seme, Flores, Daniel J., Kelly, Elizabeth J., Ren, Kuishu, Roque, Richard, Rosenthal, Kim, Streicher, Katie, Tuffy, Kevin M., Bond, Nicholas J., Cornwell, Owen, Bouquet, Jerome, Cheng, Lily I., Dunyak, James, Huang, Yue, Rosenbaum, Anton I., Reddy, Venkatesh Pilla, Andersen, Hanne, Carnahan, Robert H., Crowe, James E., Kuehne, Ana I., Herbert, Andrew S., Dye, John M., Bright, Helen, Kallewaard, Nicole L., Pangalos, Menelas N., Esser, Mark T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939769/ https://www.ncbi.nlm.nih.gov/pubmed/35076282 http://dx.doi.org/10.1126/scitranslmed.abl8124

Ejemplares similares

Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring
por: Brady, Tyler, et al.
Publicado: (2022)

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
por: Levin, Myron J., et al.
Publicado: (2022)

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019
por: Levin, Myron J, et al.
Publicado: (2022)

1143. Prophylactic and Therapeutic Activity of AZD7442 (Tixagevimab/Cilgavimab) in SARS-CoV-2 Hamster Challenge Models
por: Loo, Yueh-Ming, et al.
Publicado: (2022)

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
por: Roe, Tiffany L., et al.
Publicado: (2023)

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults
por: Levin, Myron J, et al.
Publicado: (2021)

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
por: Forte-Soto, Pablo, et al.
Publicado: (2023)

Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
por: Tuffy, Kevin M, et al.
Publicado: (2023)

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection
por: Bender Ignacio, Rachel A., et al.
Publicado: (2022)

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
por: Case, James Brett, et al.
Publicado: (2022)

Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination
por: Mu, Ruipeng, et al.
Publicado: (2022)

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
por: Hobbs, F. D. Richard, et al.
Publicado: (2023)

1354. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of COVID-19: 15-Month Final Analysis of the PROVENT Phase 3 Study
por: Levin, Myron J, et al.
Publicado: (2023)

2733. Evusheld (AZD7442) Uptake and COVID-19 Outcomes in Solid Organ Transplant Recipients: A Secondary Analysis
por: Hayek, Haya, et al.
Publicado: (2023)

Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation
por: de Lamballerie, Xavier, et al.
Publicado: (2023)

1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study
por: Levin, Myron J, et al.
Publicado: (2023)

529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study
por: Richard Hobbs, F D, et al.
Publicado: (2023)

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
por: Stuver, Robert, et al.
Publicado: (2022)

AZD7442 utilization for Pre-Exposure Prophylaxis Against COVID-19 in a French Early Access Program
por: Artaud, C, et al.
Publicado: (2023)

A scalable and high yielding SARS-CoV-2 spike protein receptor binding domain production process
por: Riguero, Valeria, et al.
Publicado: (2023)

Profile of patients with chemical injury and sensitivity.
por: Ziem, G, et al.
Publicado: (1997)

Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL
por: Benjamini, Ohad, et al.
Publicado: (2022)

EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population
por: Sutton, K, et al.
Publicado: (2022)

Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies
por: Chang, Andres, et al.
Publicado: (2023)

394. Consistency of AZD7442 (Cilgavimab/Tixagevimab) Pharmacokinetics Across Prophylaxis and Treatment and Adult and Pediatric Participants: Application of Population Pharmacokinetics to Enable Rapid Decision-Making During the COVID-19 Pandemic
por: Clegg, Lindsay E, et al.
Publicado: (2023)

Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
por: Laracy, Justin C., et al.
Publicado: (2023)

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
por: Spencer, Alexandra J, et al.
Publicado: (2022)

SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience
por: Pulvirenti, Federica, et al.
Publicado: (2023)

Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice
por: Cayatte, Corinne, et al.
Publicado: (2017)

Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC
por: Jondreville, Ludovic, et al.
Publicado: (2022)

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
por: Montgomery, Hugh, et al.
Publicado: (2022)

Combined treatments with AZD5363, AZD8542, curcumin or resveratrol induce death of human glioblastoma cells by suppressing the PI3K/AKT and SHH signaling pathways
por: Mejía-Rodríguez, Rosalinda, et al.
Publicado: (2023)

Structural and genetic basis for development of broadly neutralizing influenza antibodies
por: Lingwood, Daniel, et al.
Publicado: (2012)

Development of and insights from systems pharmacology models of antibody‐drug conjugates
por: Lam, Inez, et al.
Publicado: (2022)

Harnessing Clinical Trial and Real-World Data Towards an Understanding of Sex Effects on Drug Pharmacokinetics, Pharmacodynamics and Efficacy
por: Oi Yan Chan, Joyce, et al.
Publicado: (2022)

1355. The SARS-CoV-2 Monoclonal Antibody AZD3152 Potently Neutralizes Historical and Emerging Variants and is Being Developed for the Prevention and Treatment of COVID-19 in High-risk Individuals
por: Francica, Joseph R, et al.
Publicado: (2023)

Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug–drug interaction prediction
por: Gill, Jaidip, et al.
Publicado: (2022)

Evaluating the performance of machine‐learning regression models for pharmacokinetic drug–drug interactions
por: Gill, Jaidip, et al.
Publicado: (2022)

2641. Nirsevimab binding-site conservation in RSV F protein between 2015 and 2022: The US OUTSMART-RSV surveillance study
por: Morehouse, Christopher A, et al.
Publicado: (2023)

94. Pooled analysis of nirsevimab resistance through 150 days post dose in preterm and term infants
por: Abram, Michael E, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9p4bj861pnvcg7dda0337h2mj2